Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: Role of prostaglandins and inflammatory response

Life Sciences

Volumn 74, Issue 7, 2004, Pages 873-884

  Villegas, Isabel ^a   La Casa, Carmen ^a   De La Lastra, Catalina Alarcón ^a   Motilva, Virginia ^a   Herrerías, Juan Manuel ^a   Martín, María José ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

COX 2 inhibitors; Inflammatory response; Meloxicam; Nonsteroidal anti inflammatory drugs (NSAID); PGE2; Piroxicam

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; HYDROCHLORIC ACID; MELOXICAM; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIET RESTRICTION; DISEASE SEVERITY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HEMORRHAGIC GASTRITIS; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; STOMACH MUCOSA LESION; STOMACH PROTECTION;

ANIMALIA;

EID: 0344196769     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.07.021     Document Type: Article

References (48)

1. Albengres E., Urien S., Barre J., Nguyen P., Bree F., Jolliet P., Tillement J.P., Tsai R.S., Carrupt P.A., Testa B. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. International Journal of Tissue Reactions. 15:1993;125-134.
2. Andrews F.J., Malcontenti-Wilson C., O'Brien P.E. Effect of nonsteroidal antiinflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. American Journal of Physiology. 266:1994;G657-G664.
3. Ávila J.R., Alarcón de la Lastra C., Martín M.J., Motilva V., Luque I., Delgado D., Esteban J., Herrerías J.M. Role of endogenous sulphydryls and neutrophil infiltration in the pathogenesis of gastric mucosal injury induced by piroxicam in rats. Inflammation Research. 45:1996;83-88.
4. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scandinavian Journal of Rheumatology. 25(Suppl. 102):1996;29-37.
5. Berenguer B., Alarcón de la Lastra C., Moreno F.J., Martín M.J. Chronic gastric ulcer healing in rats subjected to selective and non selective cyclooxygenase-2 inhibitors. European Journal of Pharmacology. 442(1-2):2002;125-135.
6. Berenguer B., Martín M.J., Motilva V., Herrerías J.M., Alarcón de la Lastra C. Different effects of COX-1 and COX-2 inhibitors on normal and inflamed gastric mucosa [abstract]. 8th United European Gastroenterology Week (UEGW), Brussels, Belgium, November 25-30, 2000. Gut. vol. 47 (Supl. 3):2000;A85.
7. Björkenheim J.M., Helland J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. Journal of Internal Medicine Research. 13:1985;263-269.
8. Bohl D., Gaussman H., Vorberg G. A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis. International Journal of Clinical Pharmacology and Therapeutic Toxicology. 28:1990;416-419.
9. Bradford M.M. A rapid and sensitive method for the cuantification of microgram quantities of protein utilizing the principle of protein-dye binding. Annals of Biochemistry. 72:1976;248-254.
10. Brzozowski T., Konturek P.C., Konturek S.J., Drozdowicz D., Pajdo R., Pawlik M., Brzozowska I., Hahn E.G. Expression of cyclooxygenase (COX)-1 and COX-2 in adaptive cytoprotection induced by mild stress. Journal of Physiology Paris. 94:2000;83-91.
11. Churchill L., Graham A.G., Shih C.K., Pauletti D., Farina P.R., Grob P.M. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology. 4:1996;125-135.
12. Cryer B., Dubois A. The advent of highly selective inhibitors of cyclooxygenase, a review. Prostaglandins and Other Lipid Mediators. 56(5-6):1998;341-361.
13. Degner F., Türck D., Pairet M. Pharmacological, pharmacokinetic and clinical profile of meloxicam. Drugs of Today. 34(Suppl. A):1998;1-22.
14. Engelhardt G., Bögel R., Schnitzer C., Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochemical Pharmacology. 51:1996;29-38.
15. Engelhardt G., Homma D., Schlegel K., Utzman R., Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Research. 44:1995;423-433.
16. Grisham M.B., Beniot J.N., Granger D.N. Assessment of leukocyte in involvement during ischemia and reperfusion of the intestine. Packer I., Glazer A.N. Methods in enzymology. Oxygen radicals in biological systems. 1990;729-741 Academic Press, San Diego.
17. Hawkey C.J. COX-2 inhibitors. Lancet. 353:1999;307-314.
18. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., Hawkey C.J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut. 47:2000;762-770.
19. Kataoka H., Horie Y., Koyama R., Nakatsugi S., Furukawa M. Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach. Digestive Diseases and Sciences. 45:2000;1366-1375.
20. Lesch C.A., Gilbertsen R.B., Song Y., Dyer R.D., Schrier D., Kraus E.R., Sánchez B., Guglietta A. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats. Journal of Pharmacology and Experimental Therapeutics. 287:1998;301-306.
21. Mandell B.F. General tolerability and use of nonsteroidal anti-inflammatory drugs. American Journal of Medicine. 107(6A):1999;72S-77S.
22. Martín M.J., Alarcón de la Lastra C., Ávila J.R., Motilva V., Luque I., Esteban J., Herrerías J.M. Role of vascular mechanisms involved in the acute gastric mucosal injury induced by droxicam and piroxicam in rats. Pharmaceutical Science. 3:1997;137-141.
23. Martín M.J., Berenguer B., Herrerías J.M., Moreno J., Alarcón de la Lastra C. Effects of selective and non selective COX-2 inhibitors on chronic gastric ulcer healing. Role of prostaglandins and COX expression [abstract]. 23th Congress of the Spanish Society of Pharmacology, Alicante, Spain, September 24-27, 2000. Methods and Findings in Experimental Clinical Pharmacology. vol. 22:2000;511.
24. Martín M.J., Jiménez M.D., Alarcón de la Lastra C., Herrerías J.M., Bruseghini L., Esteras A., Motilva V. Protective effect of L-arginine against ibuprofen-induced gastric injury in rats. Pharmaceutical Science. 3:1997;609-612.
25. McCarthy D.M. Nonsteroidal anti-inflammatory drugs: the clinical dilemas. Scandinavian Journal of Gastroenterology. 192(Suppl. 27):1992;9-16.
26. McKenna F. COX-2: separating myth from reality. Scandinavian Journal of Rheumatology. 28(Suppl. 109):1999;19-29.
27. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T., Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 112:1997;387-397.
28. Motilva V., Martín M.J., Luque M.I., Alarcón de la Lastra C. Role of polymorphonuclear leukocytes and oxygen-derived free radicals in chronic gastric lesion induced by acetic acid in rat. General Pharmacology. 27:1996;545-550.
29. Naito Y., Yoshikawa T., Yoshida N., Kondo M. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury. Digestive Diseases and Sciences. 43(Suppl. 9):1998;30S-34S.
30. Patrignani P., Panara M.R., Sciulli M.G., Santini G., Renda G., Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. Journal of Physiology and Pharmacology. 48:1997;623-631.
31. Sánchez S., Martín M.J., Ortiz P., Motilva V., Alarcón de la Lastra C. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac. Digestive Diseases and Sciences. 47:2002;1389-1398.
32. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Nakama A., Takei Y., Nagano K., Matsui H., Kawano S., Hori M. Expression of cyclooxygenase-2 gene in gastric epithelium. Journal of Clinical Gastroenterology. 25(Suppl. 1):1997;S105-S110.
33. Schmassmann A., Peskar B.M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. British Journal of Pharmacology. 123:1998;795-804.
34. Simon L.S. Role and regulation of cyclooxygenase-2 during inflammation. American Journal of Medicine. 106(5B):1999;37S-42S.
35. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. American Journal of Medicine. 105(1B):1998;31S-38S.
36. Sun W.H., Tsuji S., Tsujii M., Gunawan E.S., Sawaoka H., Kawai N., Iijima H., Kimura A., Kakiuchi Y., Yasumaru M., Sasaki Y., Kawano S., Hori M. Cyclo-oxygenase-2 inhibitors suppress epithelial cell kinetics and delay gastric wound healing in rats. Journal of Gastroenterology and Hepatology. 15:2000;752-761.
37. Takahashi S., Shigeta J., Inoue H., Tanabe T., Okabe S. Localization of cycloxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. American Journal of Physiology. 275(5 Pt. 1):1998;G1137-G1145.
38. Tavares I.A. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa. Alimentary Pharmacology and Therapeutics. 14:2000;795-799.
39. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. American Journal of Medicine. 104(3A):1998;2S-8S.
40. Villegas I., Alarcón de la Lastra C., La Casa C., Motilva V., Martín M.J. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats. European Journal of Pharmacology. 414:2001;79-86.
41. Villegas I., Martín M.J., La Casa C., Motilva V., Alarcón de la Lastra C. Effects of meloxicam on oxygen radical generation in rat gastric mucosa. Inflammation Research. 49:2000;361-366.
42. Wallace J.L., Granger D.N. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends in Pharmacological Sciences. 13:1992;129-131.
43. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by nonsteroidal antiinflammatory drugs is a neutrophil-dependent process. American Journal of Physiology. 259(3 Pt. 1):1990;G462-G467.
44. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 119:2000;706-714.
45. Warner T.D., Giuliano F., Vojnovic I., Bukada A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America. 96:1999;7563-7568.
46. Waterworth R.F., Waterworth S.M., Taylor K.M. A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. European Journal of Rheumatology Inflammation. 8:1985;21-27.
47. Yamamoto H., Tanaka A., Kunikata T., Hirata T., Kato S., Takeuchi K. Inducible types of cyclooxygenase and nitric oxide synthase in adaptive cytoprotection in rat stomachs. Journal of Physiology Paris. 93:1999;405-412.
48. Zizic T.M., Sutton J.D., Stevens M.B. Long-term experience with piroxicam in osteoarthritis. Seminars in Arthritis Rheumatoid. 14(Suppl. 1):1985;14-19.